Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jaguar HealthJAGX -6.59%38 Days Payable is 431.47 as of Jun. 2026, which is 52% below its 10-year median of 900.14. GuruFocus rates JAGX with a GF Score™ of 38/100 and a GF Value™ of $123.19 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 708 Biotechnology companies, Jaguar Health ranks better than 79.1% on this metric.
The historical rank and industry rank for Jaguar Health's Days Payable or its related term are showing as below:
JAGX'
s Days Payable Range Over the Past 10 Years
Min: 496.89 Med: 900.14 Max: 3828.99
Current: 496.89
During the past 13 years, Jaguar Health's highest Days Payable was 3828.99. The lowest was 496.89. And the median was 900.14.
JAGX's Days Payable is ranked better than 79.1% of 708
companies
in the Biotechnology industry
Industry Median: 111.165
vs JAGX: 496.89
Jaguar Health's Days Payable
declined
from Jun. 2025 (1,181.32) to Jun. 2026 (431.47).
It may suggest that Jaguar Healthaccelerated paying its suppliers.
The historical data trend for Jaguar Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jaguar Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Jaguar Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Jaguar Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health (JAGX) has a Days Payable of 431.47 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jaguar Health and its competitors. This is 52% below median its historical median of 900.14. Over the past decade, Jaguar Health's Days Payable has ranged from 496.89 to 3,828.99. According to the industry distribution chart, Jaguar Health ranks #148 out of 708 companies in the Biotechnology industry, placing it in the top 20.9%.
Is Jaguar Health's Days Payable too high?
Jaguar Health's current Days Payable of 431.47 is 52% below median its 10-year median of 900.14. Over the past 10 years, this metric has ranged from a low of 496.89 to a high of 3,828.99. The Biotechnology industry median Days Payable is 111.17. Jaguar Health's value of 431.47 is 288.1% above this industry median. Based on the distribution chart, Jaguar Health ranks #148 out of 708 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jaguar Health has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Days Payable compare to TCRT and LABT?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #148 out of 708 companies for Days Payable. This places Jaguar Health in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 111.17. Jaguar Health's value of 431.47 is 288.1% above this benchmark. Historically, Jaguar Health's own Days Payable has ranged from 496.89 to 3,828.99 over the past decade. While the company's 10-year median is 900.14 vs. the industry median of 111.17, Jaguar Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jaguar Health's current Days Payable of 431.47 is 288.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jaguar Health and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jaguar Health's current Days Payable is 431.47, which is 52% below median its own 10-year median of 900.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Based on GuruFocus' analysis, Jaguar Health (JAGX) is currently considered Possible Value Trap. The stock's GF Value™ is $123.19, compared to a current price of $0.87 — trading 99.3% below its estimated fair value. The current Days Payable is 431.47, which is 52% below median its 10-year median of 900.14 and 288.1% above the Biotechnology industry median of 111.17. Jaguar Health's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Jaguar Health (JAGX), the current Days Payable is 431.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jaguar Health (JAGX) Overvalued in 2026?
Based on GuruFocus' analysis, Jaguar Health stock appears to be undervalued.
The current stock price of $0.87 is trading 99.3% below its estimated GF Value™ of $123.19.
GuruFocus considers Jaguar Health to be Possible Value Trap.
Key valuation signals for JAGX:
Days Payable: 431.47 (52% below median its 10-year median of 900.14)
GF Value™: $123.19 vs. price of $0.87 (99.3% below fair value)
Industry Position: 288.1% above the Biotechnology median (#148 of 708)
No single metric tells the full story. See the JAGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
38GF Score
Get the complete analysis for JAGX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAGX has been successfully added to your 
